Pharmacokinetic study of meropenem in healthy beagle dogs receiving intermittent hemodialysis


*College of Veterinary Medicine, Chungnam National University, Daejeon, Korea; †Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon, Korea; ‡Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Korea; §College of Pharmacy, Gachon University, Incheon, Korea


Meropenem, a second carbapenem antimicrobial agent with a broad spectrum of activity, is used to treat sepsis and resistant-bacterial infections in veterinary medicine. The objective of this study was to identify the pharmacokinetics of meropenem in dogs receiving intermittent hemodialysis (IHD) and to determine the proper dosing in renal failure patients receiving IHD. Five healthy beagle dogs were given a single i.v. dose of 24 mg/kg of meropenem and received IHD. The blood flow rate, dialysate flow, and ultrafiltration rate were maintained at 40 mL/min, 300 mL/min, and 40 mL/h, respectively. Blood samples were collected for 24 h from the jugular vein and from the extracorporeal arterial and venous line. Urine samples and dialysate were also collected. The concentrations of meropenem were assayed using HPLC/MS/MS determination. The peak plasma concentration was 116 ± 37 µg/mL at 15 min. The systemic clearance was 347 ± 117 mL/h/kg, and the steady-state volume of distribution was 223 ± 67 mL/kg. Dialysis clearance was 71.1 ± 34.3 mL/h/kg, and the extraction ratio by hemodialysis was 0.455 ± 0.150. The half-life ($T_{1/2}$) in dogs with IHD decreased compared with those without IHD, and the reduction in $T_{1/2}$ was greater in renal failure patients than in normal patients. Sixty-nine percent and 21% of the administered drug were recovered by urine and dialysate in the unchanged form, respectively. In conclusion, additional dosing of 24 mg/kg of meropenem after dialysis could be necessary according to the residual renal function of the patient based on the simulated data.

(Paper received 7 July 2015; accepted for publication 20 April 2016)

Tae-Sung Koo, Graduate School of New Drug Discovery and Development, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 305-764, Korea. E-mail: kootae@cnu.ac.kr

Kyoung-Won Seo, College of Veterinary Medicine, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 305-764, Korea. E-mail: kwseo@cnu.ac.kr

INTRODUCTION

Antibiotics are frequently used in patients receiving renal replacement therapy (RRT). According to reports in human medicine, infectious disease and acute kidney injury (AKI) often occur concurrently, and the related mortality is high (Hoste et al., 2006; Roberts et al., 2012). In veterinary medicine, infection is reported as the second most common etiology of AKI (Eatroff et al., 2012), and the incidence of AKI secondary to sepsis is 12% (Kenney et al., 2010). In renal disease, neutrophil dysfunction can make patients susceptible to infections (Cendoroglo et al., 1999). Therefore, antibiotic use is mandatory in patients with renal failure.

Meropenem is a second carbapenem antimicrobial agent with broad spectrum activity against gram-positive, gram-negative, and anaerobic bacteria (Bidgood & Papich, 2002). Meropenem is used to treat bacteremia, sepsis, and resistant-bacterial infections in veterinary medicine (Papich, 2013). Meropenem has higher activity against Pseudomonas aeruginosa and Enterobacteriaceae than does imipenem in vitro (Jones et al., 1989). It is also stable at dehydropeptidase-1 (DHP-1) and is less nephrotoxic than imipenem, and adverse reactions are rarely observed (Chimata et al., 1993; Hellinger & Brewer, 1999; Bidgood & Papich, 2002; Plumb, 2011).

The molecular weight of meropenem is 386.46 Da, and meropenem has low-protein binding (11.87%) and low volume of
distribution (372 ± 53 mL/kg) (Bidgood & Papich, 2002). These pharmacokinetic properties of meropenem allow it to be readily removed by RRT.

Despite the significance of the pharmacokinetic data for determination of the proper dosing, information about the pharmacokinetics of meropenem in dogs receiving intermittent hemodialysis (IHD) is not available. Therefore, we investigated the pharmacokinetics of meropenem in dogs receiving IHD and determined the proper dosing in renal failure patients receiving IHD.

MATERIALS AND METHODS

Animals

Five adult beagle dogs (five males) weighing from 7.94 to 11.4 kg were included in this study. The dogs were maintained for experimental purposes, housed individually in cages, fed commercial dry food, and given free access to water. All dogs were screened by physical examination, thoracic radiography, complete blood cell count, serum biochemistry, and urinalysis. All dogs were fasted for 12 h before drug administration and were fed after dialysis. The experiment was conducted in accordance with the Guide for the Care and Use of Laboratory Animals and was approved by Chungnam National University (no.CNU-00526).

Drug administration

Meropenem trihydrate (Meropen, Yuhan Co., Seoul, Korea) was prepared in normal saline at 20 mg/mL. Dogs were administered a single dose of 24 mg/kg of meropenem intravenously over a period of 15 min through the cephalic vein.

Dialysis design

A 14-French, 15-cm, double-lumen catheter (Hemodialysis catheter, Arrow International) was placed in the right jugular vein under general anesthesia. Anesthesia was induced and maintained with isoflurane (Ifran, Hana Pharm). Catheter placement was performed 24 h before meropenem infusion. Hemodialysis was initiated at the end of the infusion and was performed for 5 h with a 4008 S dialyzer unit (Fresenius Medical Care, Homburg, Germany). A pediatric high-flux dialyzer (FX paed; Fresenius Medical Care, Homburg, Germany) was used as an artificial kidney, its membrane material was helixone, and the effective surface area was 0.2 m². The total blood volume processed was 12 L, and the blood flow rate (Qb) was maintained at 40 mL/min. The dialysate flow rate (Qd) was 300 mL/min. The ultrafiltration rate was 40 mL/h, and the target volume was 200 mL. The anticoagulation agent was heparin, and the target ACT was 180–200 sec.

Sampling

Blood samples (<2 mL) were collected from the jugular vein at 0, 0.083, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24 h after infusion. Additionally, blood samples were collected from arterial and venous lines of the extracorporeal circuit at 0, 0.083, 0.5, 1, 2, 3, 4, and 5 h after the end of infusion. Blood samples were collected in heparinized tubes and were centrifuged at 1000 × g for 10 min and kept at −80 °C until analysis. Urine samples were collected through urinary catheter in three periods: from 0 to 2, 2 to 5, and 5 to 12 h after the end of infusion. Spent dialysate was collected in a 100-L plastic barrel, and a representative sample (1.5 mL) was collected in an Eppendorf tube. The total spent dialysate volume was calculated from the dialysate flow. All samples were immediately stored at −80 °C and protected from light until analysis.

Analytical method

An aliquot (50 μL) of internal standard solution (cephalexin 1 μg/mL in acetonitrile) and 200 μL of acetonitrile were added to an aliquot (50 μL) of plasma to induce the precipitation of plasma proteins. For the diluted urine and dialysate samples, 400 μL of acetonitrile was added. Separation was achieved using a HILIC Silica (Waters Atlantis, 3 μm, 2.1 × 50 mm) column with an isocratic mobile phase comprising 0.2% formic acid in 40:60 (v/v) water:acetonitrile, and detection was performed using a tandem quadrupole mass spectrometer (API 4000; Applied Biosystems/MDS SCIEX, Foster City, CA, USA) by multiple-reaction monitoring via an electrospray ionization source at m/z 684.2 to 141.0 for meropenem and m/z 348.2 to 158.1 for cephalexin. The quantifiable range for plasma samples was from 0.01 to 10 μg/mL with a coefficient of variation (CV) less than 14.3% and relative error (RE) less than 11.9% except 0.01 ng/mL (18.2%). In the case of urine, the quantifiable range was from 0.03 to 30 μg/mL with CV less than 7.46% and RE less than 11.0%. In the case of dialysate, the quantifiable range was from 0.01 to 1 μg/mL with CV less than 12.0% except 0.01 ng/mL (19.8%) and RE less than 11.2%. The recovery was over 95% in all matrixes. Like Huang’s report (Huang et al., 2014), significant matrix effect was observed in all matrices (11.4, 19.1 and 16.6% in plasma, urine, and dialysate, respectively) but that effect did not affect the result. The retention times of meropenem and cephalexin were 1.89 min and 0.84 min, respectively.

Pharmacokinetic analysis

The plasma concentration–time profile for each dog was analyzed using the WinNonlin 4.1 (Pharsight) program to determine the pharmacokinetic parameters. To determine the optimal model and weight schemes, values determined with Akaike’s information criterion (AIC) and Schwarz Bayesian Criterion (SBC) were compared. Goodness of fit was assessed statistically by the F-test.

Renal clearance (CL_R) and dialysis clearance (CL_D) were calculated as

\[
CL_{R/D} = \frac{\text{Amount}_{\text{urine or dialysate}}/\text{AUC}_{0-\infty}}{\text{CL}_{R/D}}
\]

CL_D and the extraction ratio by hemodialysis (ERD) were calculated by the following equations (Qp: pumping rate for

© 2016 John Wiley & Sons Ltd

\[
\text{CL}_0 = \frac{[Qp \cdot C_A - (Qp - Quf) \cdot C_v]}{C_A}
\]

(2)

\[
\text{ERD} = \frac{\text{CL}_0}{[Qp + (Qp - Quf)]/2}
\]

(3)

Only values during IHD were used for the pharmacokinetic analysis, and the parameters were calculated for each animal and then averaged.

**Determination of dosage regimen**

Plasma concentrations were simulated to determine the meropenem dosage regimen, based on mean plasma concentration–time profiles. A y²-weighted two-compartment model was used to analyze results at a constant rate of intravenous infusion and with first-order output. In calculating CL for anuric renal failure and IHD, the value of CLr and CLd was subtracted and added, respectively. The change of renal function and the application of hemodialysis were assumed to affect the elimination rate constant \(k_d\) alone.

For antimicrobial effect of carbapenem drugs, the amount of time that the free drug concentration remains above MIC \((\geq\text{MIC})\) should be over 33–40% of the drug (Drusano & Hutchison, 1995; Mouton et al., 2000). Due to the lack of minimal inhibitory concentration (MIC) data for meropenem in veterinary medicine, the MIC value for meropenem in humans was used. Considering its resistance against infection, such as with *Pseudomonas*, and the difference in plasma protein binding (PPB) between dog and human, the MIC of meropenem in dogs was regarded as 1.1 μg/mL.

**RESULTS**

The total amount of meropenem administered to each dog was 230 ± 40 mg. No adverse events were observed after the administration of meropenem.

The average plasma concentration–time profiles of meropenem are described in Fig. 1. There was a multi-exponential decline in the plasma meropenem level, and plasma meropenem was no longer detected in any dogs 12 h after the end of infusion. Analysis showed that a three-compartment model at a constant rate of intravenous infusion did not fit the concentration data. Based on the values obtained from the sum of weighted residual squares, as well as AIC and SBC criteria, of one- and two-compartment model analyses, the two-compartment model with a constant rate of intravenous infusion was determined to optimally fit the plasma concentration data (Table 1). An F-test also showed that the y²-weighted two-compartment model was superior to other models (data not shown).

The pharmacokinetic data using y²-weighted two-compartment model with constant rate intravenous infusion and constant rate intravenous infusion are described in Table 1. After the i.v. infusion of meropenem, the peak plasma concentration \((C_{max})\) was 116 ± 37 μg/mL at 15 min. The mean systemic plasma clearance \((\text{CL})\) was 347 ± 117 mL/h/kg, and the mean steady-state volume of distribution \((V_{ss})\) was 223 ± 67 mL/kg.

The mean amount of meropenem in urine in the first 2 h after the end of infusion was 142 ± 90 mg; for 0–5 h, it was 158 ± 71 mg; and for 0–12 h, it was 159 ± 72 mg. The main proportion (68.9%) of the administered drug was excreted by the urine in an unchanged form, and 89.2% of the urine excretion occurred in the first 2 h. The mean amount of meropenem recovered from the dialysate was 47.2 ± 22.8 mg, and this value was approximately 20.5% of the administered drug. Based on the concentration of meropenem in the dialysate, dialysis clearance \((\text{CL}_d)\) was calculated as 71.1 ± 34.3 mL/h/kg. As calculated using the method of Gotch, CLd was 65.4 ± 27.5 mL/h/kg. The mean ERD value was 0.455 ± 0.150.

Table 2 shows the clearance and elimination half-life in dogs with various degrees or renal functions with/without IHD. Calculations were based on the pharmacokinetic data from average concentration and performed using on equations 4 \((k_{el}: \text{elimination rate constant})\)

\[
T_{1/2} = \ln 2/k_{el}
\]

(4)

Group 1 included healthy beagle dogs with normal renal function: the clearance of meropenem was 276 mL/h/kg, and \(T_{1/2}\) was 1.14 h. If IHD were applied to this group, \(T_{1/2}\) would decrease to 80% of \(T_{1/2}\) compared with the value for group 1 during the dialysis period. Assuming an anuric state of renal failure, additional clearance of the dialyzer would increase the total clearance more than twofold compared with the 26% increase observed in groups with normal renal function. Accordingly, the dialysis clearance of meropenem
Table 1. Pharmacokinetic parameters of meropenem in healthy beagle dogs after intravenous infusion of meropenem (24 mg/kg for 0.25 h) during IHD

<table>
<thead>
<tr>
<th>PK Parameters</th>
<th>Dog 1</th>
<th>Dog 2</th>
<th>Dog 3</th>
<th>Dog 4</th>
<th>Dog 5</th>
<th>Mean ± S.D.</th>
<th>Mean Conc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>T&lt;sub&gt;max&lt;/sub&gt; (h)</td>
<td>0.250</td>
<td>0.250</td>
<td>0.250</td>
<td>0.250</td>
<td>0.250</td>
<td>0.250 ± 0.000</td>
<td>0.250</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; (µg/mL)</td>
<td>163</td>
<td>124</td>
<td>70.2</td>
<td>90.0</td>
<td>135</td>
<td>116 ± 37</td>
<td>116</td>
</tr>
<tr>
<td>T&lt;sub&gt;1/2&lt;/sub&gt; (h)</td>
<td>0.734</td>
<td>0.843</td>
<td>0.714</td>
<td>1.08</td>
<td>1.18</td>
<td>0.911 ± 0.211</td>
<td>0.813</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;0-∞&lt;/sub&gt; (µg·h/mL)</td>
<td>116</td>
<td>81.6</td>
<td>49.1</td>
<td>59.1</td>
<td>87.9</td>
<td>78.8 ± 26.3</td>
<td>79.8</td>
</tr>
<tr>
<td>CL (mL/h/kg)</td>
<td>215</td>
<td>307</td>
<td>509</td>
<td>423</td>
<td>285</td>
<td>347 ± 117</td>
<td>313</td>
</tr>
<tr>
<td>V&lt;sub&gt;sst&lt;/sub&gt; (mL/kg)</td>
<td>152</td>
<td>198</td>
<td>310</td>
<td>275</td>
<td>181</td>
<td>223 ± 67</td>
<td>208</td>
</tr>
</tbody>
</table>

T<sub>max</sub> = Time until maximum concentration. C<sub>max</sub> = Maximum concentration. T<sub>1/2</sub> = Elimination half-life. AUC = Area under the curve. MRT = Mean residence time. CL = Clearance. V<sub>ss</sub> = Apparent volume of distribution.

*Harmonic mean.

Table 2. Prediction of the elimination half-life based on pharmacokinetic data from average concentration

<table>
<thead>
<tr>
<th>Group</th>
<th>Condition</th>
<th>Final Clearance (mL/h/kg)</th>
<th>Half-life during IHD (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Normal without IHD</td>
<td>Cl&lt;sub&gt;rel&lt;/sub&gt; + Cl&lt;sub&gt;Others&lt;/sub&gt;</td>
<td>1.14</td>
</tr>
<tr>
<td></td>
<td></td>
<td>216 + 37 = 249</td>
<td>(T&lt;sub&gt;1/2&lt;/sub&gt;)</td>
</tr>
<tr>
<td>2</td>
<td>Normal with IHD</td>
<td>Cl&lt;sub&gt;rel&lt;/sub&gt; + Cl&lt;sub&gt;Others&lt;/sub&gt;</td>
<td>0.81</td>
</tr>
<tr>
<td></td>
<td></td>
<td>216 + 33 + 64 = 313</td>
<td>(0.8T&lt;sub&gt;1/2&lt;/sub&gt;)</td>
</tr>
<tr>
<td>3</td>
<td>Anuric renal failure</td>
<td>Cl&lt;sub&gt;Others&lt;/sub&gt;</td>
<td>5.59</td>
</tr>
<tr>
<td></td>
<td></td>
<td>33</td>
<td>(7.5T&lt;sub&gt;1/2&lt;/sub&gt;)</td>
</tr>
<tr>
<td>4</td>
<td>Anuric renal failure</td>
<td>Cl&lt;sub&gt;Others&lt;/sub&gt; + Cl&lt;sub&gt;D&lt;/sub&gt;</td>
<td>2.90</td>
</tr>
<tr>
<td></td>
<td>with IHD</td>
<td>33 + 64 = 97</td>
<td>(2.6T&lt;sub&gt;1/2&lt;/sub&gt;)</td>
</tr>
</tbody>
</table>

Cl<sub>rel</sub> = Renal clearance. Cl<sub>Others</sub> = Nonrenal clearance. Cl<sub>D</sub> = Dialysis clearance. T<sub>1/2</sub> = Elimination half-life.

would be expected to account for 65.7% of the total clearance in the anuric renal failure group. However, applying IHD treatment to anuric renal failure patients would cause a significant decrease in T<sub>1/2</sub> from 8.5 h to 2.9 h during the dialysis period.

The pharmacokinetic simulations of the plasma–time concentration profile of meropenem in dogs with various renal functions and with/without IHD are described in Fig. 2.

DISCUSSION

A dosing simulation was performed based on the data from our study to assess the adequacy of adjusting the general dosage regimens in IHD dogs and to establish dose recommendations in renal patients receiving IHD.

Previous pharmacokinetic studies of meropenem have been performed in healthy beagle dogs (Harrison et al., 1989; Bidgood & Papich, 2002). In our study, the total body clearance, plasma half-life, area under curve (AUC), and volume of distribution are similar to the values determined in previous studies. According to Bidgood et al., after 20 mg/kg meropenem infusion, the total body clearance was 392 ± 91 mL/h/kg, and the plasma half-life was 0.67 ± 0.07 h. The AUC and volume of distribution were 53 ± 12 µg·h/mL and 337 ± 52 mL/kg, respectively.

Drug removal through hemodialysis was first reported by Golper et al. (Golper et al., 1985). Thereafter, numerous studies of drug removal during HD have been performed in human medicine. Considerations for drug dosing in patients under renal replacement therapy are including drug characteristics, HD prescription, and patients’ status. Drug with low-protein binding, low volume of distribution, and low molecular weight and size can be significantly removed through dialyzers (Bohler et al., 1999; Heintz et al., 2009).

In humans, meropenem and its metabolite showed significant removal through IHD, and the possibility of underdosing was reported (Thalhammer & Horl, 2000). Several studies confirmed a significant decrease in the elimination half-life during dialysis, and the reported drug removal comprised as much as 50–70% of the administered drug (Leroy et al., 1992a,b). Additional dosing of meropenem at the end of dialysis is recommended in these studies to avoid underdosing (Christensson et al., 1992; Leroy et al., 1992a,b; Chimata et al., 1993).

Meropenem removal through IHD using a helixone membrane was identified in this study. Dialysis clearance was...
calculated from the measurement of the meropenem concentration in the recovered dialysate and was calculated using the method of Gotch (Gotch, 1976). The two clearances were similar, and approximately 20.5% of the administered meropenem was removed by the dialyzer.

In general, serious renal failure reduces plasma protein binding. However, the PPB of meropenem in dogs was reported to be about 11% (Bidgood & Papich, 2002), suggesting that altered protein binding had negligible impact on renal failure and hemodialysis. Furthermore, renal dysfunction would be expected to cause decreased drug clearance proportionally to the residual renal function, and the dogs on IHD showed decreased $T_{1/2}$ and low plasma concentrations compared with those observed in off-dialysis dogs with the same renal function.

According to this simulation, the dosage regimen of 24 mg/kg, i.v., once daily is inadequate in both the on- and off-dialysis groups with normal renal function. In dogs with normal renal function, i.v. infusion of 24 mg/kg of meropenem every 8 h was adequate, regardless of the IHD treatment. In off-dialysis dogs whose renal function has failed by up to 75%, 24 mg/kg of meropenem once daily maintains its plasma concentration for sufficient time, but not in on-dialysis dogs. Applying the same interval to the IHD dogs would result in an underdosing of meropenem because $T>MIC$ does not exceed 40% of the dosing interval. Therefore, repetitive dosing of 24 mg/kg of meropenem after IHD may be required in these dogs. In contrast to dogs with 75% renal failure, anuric patients with IHD do not require meropenem re-dosing. In accordance with this simulation, 24 mg/kg of meropenem every 72 h would be sufficient to obtain a bacterial killing effect in anuric, off-dialysis dogs, and applying the same dosage to anuric patients receiving IHD would also be sufficient. Therefore, re-dosing in anuric dogs receiving IHD is not necessary.

As noted above, IHD treatment does not always correlate to re-dosing of meropenem in dogs, unlike in the human dosing guidelines. The necessity of repetitive dosing did not show consistency among groups, and this difference is thought to be caused by the residual renal function of the patient. A previous study reported the influence of the residual renal function of the patient on meropenem clearance (Isle et al., 2005). It was explained that even with the dialysis clearance of meropenem, renal clearance was the major route of elimination of the drug, and drug clearance could be influenced significantly by the patient’s renal function.

However, recent studies in human patients reported that maintaining $T>MIC$ at 33–40% of the dosing interval did not achieve the desired antimicrobial effects. In one study, optimal clinical outcomes were achieved when $T>MIC$ was maintained at over 75% of the dosing interval (Ariano et al., 2005), suggesting that the dosage regimens used in our study were insufficient. Further pharmacodynamic studies are required to assess the antimicrobial effect of meropenem and relationship between $T>MIC$ and bacterial killing effect in vivo.

This study is limited to the specific settings of IHD (blood flow, ultrafiltration rate, dialyzer membrane) and was conducted in healthy subjects; therefore, meropenem removal could be altered in different settings of IHD and in actual patients with different renal function. In addition, dosing requirements can vary in individual patients, as the simulated data are based on average plasma concentrations.

Multiple-dosing studies in patients with various degrees of renal failure at different IHD settings should be performed to obtain a conclusive recommendation for a dosage regimen.

CONCLUSIONS

This study investigated the pharmacokinetics of meropenem in healthy beagle dogs receiving IHD. Meropenem removal through IHD was identified, and underdosing occurred. Repetitive dosing of 24 mg/kg of meropenem after dialysis could be required depending on the residual renal function of the patient.

CONFLICT OF INTERESTS

The authors declare that they have no conflict of interests.

ACKNOWLEDGMENTS

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2014R1A1A4A0107297).

REFERENCES


